{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974385",
  "id": "02974385",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0947",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9kcwryl8xkl.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n**Clinical & Regulatory Highlights:**  \n- **Positive interim Phase 2 data** for amsulostat (SNT-5505) in myelofibrosis (MF):  \n  - 73% (8/11) patients achieved \u226550% symptom improvement (TSS50) at 24+ weeks.  \n  - 44% (4/9) achieved \u226525% spleen volume reduction (SVR25); 78% showed stable/reduced spleen volume.  \n  - No serious adverse events linked to treatment.  \n- **Fast Track designation** granted by FDA for amsulostat in MF.  \n- **Phase 1b/2 AZALOX trial** initiated for amsulostat in myelodysplastic syndrome (MDS).  \n- **WHO assigned INN \"amsulostat\"** for SNT-5505.  \n- **First patient dosed** in Phase 1c SATELLITE trial for keloid scars (SNT-6302).  \n\n**Financials:**  \n- **Closing cash balance:** **$15.1m** (down from $18.0m prior quarter).  \n- **Net cash outflow:** **$2.9m** (operating outflow $3.74m, offset by $0.9m from MBU sale).  \n- **R&D & staff costs:** $3.84m (93% of operating outflows).  \n\n**Upcoming Catalyst:**  \n- FDA **Type C meeting** in Q3 2025 to discuss MF Phase 2 data and pivotal trial design.  \n\n*No material capital raising or trading halt information identified.*",
  "usage": {
    "prompt_tokens": 3892,
    "completion_tokens": 352,
    "total_tokens": 4244,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T00:06:13.804926"
}